免费获得国外相关药品,最快 1 个工作日回馈药物信息

出境医 / 临床实验 / The Use of HE4 With Simple Ultrasound Rules to Predict Malignancy in a Pelvic Mass

The Use of HE4 With Simple Ultrasound Rules to Predict Malignancy in a Pelvic Mass

Study Description
Brief Summary:

Our objective is to determine if the combination of simple ultrasound features (IOTA simple rules) and a new biomarker (HE4) together with a common tumour marker (CA 125) can accurately predict ovarian cancer in women found to have a pelvic mass on ultrasound. The investigators hypothesize that the use of two biomarkers (HE4 and CA 125) in a mathematical algorithm (Risk of Malignancy Algorithm, ROMA) can be used to predict malignancy in a pelvic mass which has indeterminate ultrasound features. This is a prospective cohort study involving women undergoing operation for a pelvic mass. 720 women scheduled to have an operation to remove a pelvic mass would be recruited from 3 hospitals (QMH, UCH and PYNEH). Pre-operatively, each woman will have an ultrasound assessment using the IOTA simple rules criteria and have blood taken for tumour markers HE4 and CA 125. In women where IOTA ultrasound rules are inconclusive, 2 strategies for prediction will be compared - calculation of risk by ROMA (Strategy A) vs referral for an expert ultrasound (Strategy B). These pre-operative risk predictions will be correlated with the final pathology found at the operations.

Main outcome measures include the sensitivity, specificity, positive and negative predictive powers for Strategy A compared to Strategy B. Sensitivity and specificity will be compared using the McNemar test. Area Under the ROC Curve (AUC) will be calculated and compared using the Delong method for the 2 strategies.

The investigators expect AUC of both strategies will be similar. This would suggest that ROMA can replace expert ultrasound in the pre-operative prediction of ovarian cancer.


Condition or disease
Pelvic Mass

Study Design
Layout table for study information
Study Type : Observational
Estimated Enrollment : 720 participants
Observational Model: Other
Time Perspective: Prospective
Official Title: The Use of a New Biomarker, HE4, in Combination With Simple Ultrasound Rules in the Prediction of Malignancy in a Pelvic Mass Detected on Ultrasound
Actual Study Start Date : April 1, 2018
Estimated Primary Completion Date : April 10, 2020
Estimated Study Completion Date : September 30, 2020
Arms and Interventions
Outcome Measures
Primary Outcome Measures :
  1. sensitivity, specificity and predictive powers [ Time Frame: 3 months after last subject enrolled ]
    The group of women with inconclusive IOTA assessment will undergo further assessment by both tumour markers assessment by ROMA (Strategy A) and expert ultrasound (Strategy B). The prediction of risk of malignancy (high or low) will be correlated with the final histopathology result from the surgery. The sensitivity, specificity and predictive powers for the 2 strategies will be compared.


Secondary Outcome Measures :
  1. Best method for predicting malignancy in pelvic mass in HK [ Time Frame: 3 months after last subject enrolled ]
    The sensitivity, specificity and predictive powers for 4 different predicting methods - (i) IOTA simple rules followed by ROMA (if IOTA inconclusive), (ii) IOTA simple rules followed by expert ultrasound assessments (if IOTA inconclusive), (iii) ROMA, or (iv) RMI will be compared.

  2. Accuracy of these 4 different prediction methods in different hospital settings [ Time Frame: 3 months after last subject enrolled ]
    The sensitivity, specificity and predictive powers for these 4 different prediction methods for the 3 hospitals will be compared and factors influencing the accuracy will be explored.

  3. Performance of IOTA simple rules followed by ROMA (if IOTA inconclusive) in different histological subtypes [ Time Frame: 3 months after last subject enrolled ]
    Since the tumour markers assessed by ROMA may be more commonly raised in some subtypes (eg serous adenocarcinoma) compared to other subtypes (eg mucinous adenocarcinoma), it is possible that the performance of IOTA followed by ROMA may differ in different histological subtypes. The final histological subtypes will be obtained from the pathology reports from the surgery. The sensitivity and specificity of IOTA followed by ROMA will be compared amongst the different major histological subtypes.


Eligibility Criteria
Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Women found to have a pelvic mass on ultrasound in Hong Kong
Criteria

Inclusion Criteria:

  • Women over the age of 18
  • Found to have a pelvic mass on ultrasound, MRI, CT or PET scan
  • Scheduled for operation (laparoscopic or open) for a pelvic mass (including ovarian cystectomy and oophorectomy)
  • Women who would understand the informed consent

Exclusion Criteria:

  • Women who refused a transvaginal scan
  • Pregnant women
  • Surgical removal is delayed for more than 120 days from the date of the ultrasound examination
  • Previous history of ovarian, peritoneal or fallopian tube cancer or unknown malignancy
  • History of bilateral oophorectomy
Contacts and Locations

Contacts
Layout table for location contacts
Contact: Karen Kar Loen Chan, MBBChir +852 22554517 kklchan@hku.hk

Locations
Layout table for location information
Hong Kong
Pamela Youde Nethersole Eastern Hospital Recruiting
Hong Kong, Hong Kong
Contact: Carmen Ka Man Choi, MBBS    +852 25956815    choikm@ha.org.hk   
Queen Mary Hospital Recruiting
Hong Kong, Hong Kong
Contact: Karen Kar Loen Chan, MBBChir    +852 22554517    kklchan@hku.hk   
Sub-Investigator: Hextan Yuen Sheung Ngan, MBBS, MD         
Principal Investigator: Karen Kar Loen Chan, MBBChir         
Sub-Investigator: Vincent Yuk Tong Cheung, MBBS         
Sub-Investigator: Ka Yu Tse, MBBS, MMedsc         
Sub-Investigator: Mandy Man Yee Chu, MBBS         
Sub-Investigator: Michelle Kwan Yee Siu, Bsc, PhD         
United Christian Hospital Recruiting
Hong Kong, Hong Kong
Contact: Victoria Yu Ka Chai, MBBS    +852 39494385    cyk095a@ha.org.hk   
Sponsors and Collaborators
The University of Hong Kong
United Christian Hospital
Pamela Youde Nethersole Eastern Hospital, Hong Kong
Tracking Information
First Submitted Date January 29, 2019
First Posted Date June 12, 2019
Last Update Posted Date June 12, 2019
Actual Study Start Date April 1, 2018
Estimated Primary Completion Date April 10, 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: June 10, 2019)
sensitivity, specificity and predictive powers [ Time Frame: 3 months after last subject enrolled ]
The group of women with inconclusive IOTA assessment will undergo further assessment by both tumour markers assessment by ROMA (Strategy A) and expert ultrasound (Strategy B). The prediction of risk of malignancy (high or low) will be correlated with the final histopathology result from the surgery. The sensitivity, specificity and predictive powers for the 2 strategies will be compared.
Original Primary Outcome Measures Same as current
Change History No Changes Posted
Current Secondary Outcome Measures
 (submitted: June 10, 2019)
  • Best method for predicting malignancy in pelvic mass in HK [ Time Frame: 3 months after last subject enrolled ]
    The sensitivity, specificity and predictive powers for 4 different predicting methods - (i) IOTA simple rules followed by ROMA (if IOTA inconclusive), (ii) IOTA simple rules followed by expert ultrasound assessments (if IOTA inconclusive), (iii) ROMA, or (iv) RMI will be compared.
  • Accuracy of these 4 different prediction methods in different hospital settings [ Time Frame: 3 months after last subject enrolled ]
    The sensitivity, specificity and predictive powers for these 4 different prediction methods for the 3 hospitals will be compared and factors influencing the accuracy will be explored.
  • Performance of IOTA simple rules followed by ROMA (if IOTA inconclusive) in different histological subtypes [ Time Frame: 3 months after last subject enrolled ]
    Since the tumour markers assessed by ROMA may be more commonly raised in some subtypes (eg serous adenocarcinoma) compared to other subtypes (eg mucinous adenocarcinoma), it is possible that the performance of IOTA followed by ROMA may differ in different histological subtypes. The final histological subtypes will be obtained from the pathology reports from the surgery. The sensitivity and specificity of IOTA followed by ROMA will be compared amongst the different major histological subtypes.
Original Secondary Outcome Measures Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title The Use of HE4 With Simple Ultrasound Rules to Predict Malignancy in a Pelvic Mass
Official Title The Use of a New Biomarker, HE4, in Combination With Simple Ultrasound Rules in the Prediction of Malignancy in a Pelvic Mass Detected on Ultrasound
Brief Summary

Our objective is to determine if the combination of simple ultrasound features (IOTA simple rules) and a new biomarker (HE4) together with a common tumour marker (CA 125) can accurately predict ovarian cancer in women found to have a pelvic mass on ultrasound. The investigators hypothesize that the use of two biomarkers (HE4 and CA 125) in a mathematical algorithm (Risk of Malignancy Algorithm, ROMA) can be used to predict malignancy in a pelvic mass which has indeterminate ultrasound features. This is a prospective cohort study involving women undergoing operation for a pelvic mass. 720 women scheduled to have an operation to remove a pelvic mass would be recruited from 3 hospitals (QMH, UCH and PYNEH). Pre-operatively, each woman will have an ultrasound assessment using the IOTA simple rules criteria and have blood taken for tumour markers HE4 and CA 125. In women where IOTA ultrasound rules are inconclusive, 2 strategies for prediction will be compared - calculation of risk by ROMA (Strategy A) vs referral for an expert ultrasound (Strategy B). These pre-operative risk predictions will be correlated with the final pathology found at the operations.

Main outcome measures include the sensitivity, specificity, positive and negative predictive powers for Strategy A compared to Strategy B. Sensitivity and specificity will be compared using the McNemar test. Area Under the ROC Curve (AUC) will be calculated and compared using the Delong method for the 2 strategies.

The investigators expect AUC of both strategies will be similar. This would suggest that ROMA can replace expert ultrasound in the pre-operative prediction of ovarian cancer.

Detailed Description Not Provided
Study Type Observational
Study Design Observational Model: Other
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population Women found to have a pelvic mass on ultrasound in Hong Kong
Condition Pelvic Mass
Intervention Not Provided
Study Groups/Cohorts Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Unknown status
Estimated Enrollment
 (submitted: June 10, 2019)
720
Original Estimated Enrollment Same as current
Estimated Study Completion Date September 30, 2020
Estimated Primary Completion Date April 10, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Women over the age of 18
  • Found to have a pelvic mass on ultrasound, MRI, CT or PET scan
  • Scheduled for operation (laparoscopic or open) for a pelvic mass (including ovarian cystectomy and oophorectomy)
  • Women who would understand the informed consent

Exclusion Criteria:

  • Women who refused a transvaginal scan
  • Pregnant women
  • Surgical removal is delayed for more than 120 days from the date of the ultrasound examination
  • Previous history of ovarian, peritoneal or fallopian tube cancer or unknown malignancy
  • History of bilateral oophorectomy
Sex/Gender
Sexes Eligible for Study: Female
Ages 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Hong Kong
Removed Location Countries  
 
Administrative Information
NCT Number NCT03982914
Other Study ID Numbers UW 17-551
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement Not Provided
Responsible Party The University of Hong Kong
Study Sponsor The University of Hong Kong
Collaborators
  • United Christian Hospital
  • Pamela Youde Nethersole Eastern Hospital, Hong Kong
Investigators Not Provided
PRS Account The University of Hong Kong
Verification Date June 2019

治疗医院